Eyepoint Pharmaceuticals (EYPT) Investor Presentation - Slideshow

EYP-1901 Pipeline Program - EYP-1901 is a key pipeline program utilizing Durasert drug delivery technology[4] - Phase 2 "DAVIO 2" clinical trial in wet AMD is underway, and the NPDR "PAVIA" trial is expected to begin in September 2022[4] - Phase 1 "DAVIO" clinical trial demonstrated positive safety and efficacy data for EYP-1901[4] - EYP-1901 utilizes a bioerodible formulation of Durasert for sustained, zero-order kinetics drug release over 6-9 months[8] - In the DAVIO Phase 1 clinical trial, 53% of patients did not require supplemental anti-VEGF treatment at 6 months[18, 20] - The DAVIO Phase 1 clinical trial demonstrated a clinically significant reduction in treatment burden of 73% at 12 months[17] Financial Position - The company had $171 million in cash and investments as of June 30, 2022, providing a cash runway into the second half of 2024[5, 42] - Net product revenues in Q2 2022 were $11.3 million, a 30% increase over Q2 2021[42] - The commercial franchise is projected to break even in 2022[5, 42] YUTIQ Product - YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg is approved for the treatment of posterior segment uveitis[36] - Customer demand for YUTIQ increased by 43% in Q2 2022 compared to Q1 2022[41]